SCHEMBL18601577

SCHEMBL18601577

Cc1ccc2[nH]cc(CCNC(=O)C3CCN(c4ccc(Cl)cc4)C3=O)c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.54
MTNR1A P48039 3/20 0.53
MTNR1B P49286 3/20 0.53
ALDH1A1 P00352 2/20 0.49
HPGD P15428 1/20 0.49
SNCA P37840 2/20 0.48
SOS1 Q07889 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TSHR P16473 1/20 0.47
SPR P35270 1/20 0.47
KDM4E B2RXH2 1/20 0.47
GFER P55789 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP14 P50281 1/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL892306 0.95 SNCA (0.54) KMT2AMEN1MTNR1AMTNR1BALDH1A1
SCHEMBL892580 0.93 MTNR1A (0.55) MTNR1AMTNR1BALDH1A1HPGDSNCA
SCHEMBL892553 0.90 KMT2A (0.57) KMT2AMEN1MTNR1AMTNR1BALDH1A1
SCHEMBL892337 0.89 SNCA (0.53) KMT2AMEN1MTNR1AMTNR1BSNCA
SCHEMBL10274768 0.89 MTNR1A (0.53) MTNR1AMTNR1BALDH1A1HPGDSNCA
SCHEMBL892093 0.88 MTNR1A (0.52) KMT2AMTNR1AMTNR1BSNCASMN1; SMN2
SCHEMBL892549 0.88 MTNR1A (0.52) KMT2AMTNR1AMTNR1BALDH1A1SNCA
SCHEMBL891522 0.88 MTNR1A (0.55) MTNR1AMTNR1BSNCASMN1; SMN2TSHR
SCHEMBL892302 0.88 MTNR1A (0.52) KMT2AMEN1MTNR1AMTNR1BALDH1A1
SCHEMBL892859 0.88 SNCA (0.54) MTNR1AMTNR1BSNCASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440550-B1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV LEUVEN KATH (BE) 2017-03-15 EP claimed
US-12178805-B2 Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders REMYND N.V. (BE) 2024-12-31 US disclosed
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2020-08-13 US disclosed
EP-2440550-B1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV LEUVEN KATH (BE) 2017-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12178805-B2 Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders PDE4A, PDE12, PDE2A KMT2A 1565/4885MEN1 2921/4885MTNR1A 1212/4885
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS PDE4A, PDE12, PDE2A KMT2A 1565/4885MEN1 2921/4885MTNR1A 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.